Verona Pharma has announced positive efficacy and safety results about using nebulized ensifentrine as an add-on therapy to tiotropium (Spiriva Respimat) for treating symptomatic chronic obstructive pulmonary disease (COPD). Results from the Phase 2b clinical trial (NCT03937479) show that ensifentrine treatment, combined with maintenance tiotropium, results in…
Scientists have found that a certain protein helps cells in the airways to clear away mucus, such as the mucus that builds up in chronic obstructive pulmonary disease (COPD). This discovery, they noted, suggests that boosting the activity of this protein, called adenine nucleotide translocase (ANT), could become a…
Certain risk factors may accurately predict in-hospital mortality, or death, in people with acute exacerbations of chronic obstructive pulmonary disease (COPD), a study revealed. These factors include the need for invasive mechanical ventilation (IMV), having chronic heart failure, and having a low number of immune white blood cells,…
Pulmatrix will regain full rights to its portfolio of narrow spectrum kinase inhibitor (NSKI) medications, including the investigational therapy PUR1800 to treat acute flare in chronic obstructive pulmonary disease (COPD) and other chronic diseases of the airways.
Antidepressants and anti-anxiety medications are often prescribed to people with chronic obstructive pulmonary disease (COPD), pointing to a higher risk of psychiatric and mental health problems in this patient group, a large Dutch database study reported. These findings, its researchers noted, indicate that depression and anxiety are more common…
Respinova’s new airway device, called Pulsehaler, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). That means it can be marketed as a safe and effective medical device to ease breathing in people with airway restrictions, such as chronic obstructive pulmonary disease (COPD). “We…
Lannett is seeking the approval of a generic form of Advair Diskus (fluticasone-salmeterol powder) in the U.S. Such an approval would be expected to provide a less-expensive alternative to the inhalation treatment that generated about $3 billion in total U.S. sales for the 12 months ending in February 2021,…
Researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) have been awarded a $30,000 CHEST Foundation Research Grant to study racial differences in lung health among smokers, with an emphasis on African Americans. Lung function is an important health indicator and can be compromised by various factors,…
Long-term pulmonary rehabilitation (PR) maintenance programs can benefit people with chronic obstructive pulmonary disease (COPD) in a real-life setting, a retrospective study indicates. In fact, PR maintenance programs lasting three years or more were associated with favorable survival indicators among patients, particularly those with less severe disease,…
Patients with chronic obstructive pulmonary disease who have worse lung function and prior history of acidotic hypercapnic respiratory failure (AHRF) are more likely to develop hypercapnia, defined as excessive carbon dioxide (CO2) in the bloodstream, a new study has found. The study, “Development and Relevance of Hypercapnia in…
Get regular updates to your inbox.